Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Bullboard Posts
Post by yf4l8888on Mar 10, 2017 5:06pm
376 Views
Post# 25966241

news

news
MAKENA PROPOSES SHARE CONSOLIDATION Makena Resources Inc. intends to proceed with a consolidation of its outstanding common shares on the basis of one postconsolidation share for 20 preconsolidation shares. Currently, a total of 141,866,783 common shares in the capital of the company are issued and outstanding. Accordingly, if the consolidation is put into effect, a total of approximately 7,093,339 common shares in the capital of the company would be issued and outstanding following the consolidation, assuming there are no other changes in the issued capital of the company. There are currently an unlimited number of authorized common shares without par value. The consolidation is being proposed to allow the company greater flexibility in future financings and is subject to approval of the TSX Venture Exchange. Seth Kay, currently a director of Makena, will replace Negar Adam as the incoming president and secretary. Mr. Adam will remain as a consultant to the company.
Bullboard Posts